

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **APPOINTMENT OF AUDITORS**

Reference is made to the announcement (the “**Announcement**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) dated 8 July 2020 in relation to the resignation of Crowe (HK) CPA Limited (“**Crowe**”) as auditor of the Company with effect from 8 July 2020. Capitalised terms used herein, unless otherwise defined, shall have the same meanings as those defined in the Announcement.

The Board announces that it was informed by EY on 20 July 2020 that the relevant audit engagement acceptance procedure and the formal acceptance of EY as Company’s auditor have completed. Accordingly, with the recommendation of the Audit Committee and the approval of the Board, EY is appointed as the Company’s auditor on 20 July 2020 to fill the causal vacancy following the resignation of Crowe and hold office until the conclusion of the next annual general meeting of the Company.

By order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Sichuan, the PRC, 20 July 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang.*